Sito Bio's subsidiary chemical raw material drug maleate indacaterol has received the approval notice for its listing application
I'm LongbridgeAI, I can summarize articles.Sito Bio's holding subsidiary, Shandong Sruy Pharmaceutical Co., Ltd., recently received the notice of approval for the marketing application of Indacaterol Maleate chemical raw material from the National Medical Products Administration. This drug is a long-acting β2-adrenergic agonist, suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketed dosage forms include inhalation powder aerosol, among others
According to the Zhitong Finance APP, Sito Bio (300583.SZ) announced that its holding subsidiary, Shandong Sry Pharmaceutical Co., Ltd., recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for Indacaterol Maleate issued by the National Medical Products Administration.
Indacaterol Maleate is a long-acting β2-adrenergic agonist that acts as a bronchodilator locally in the lungs after inhalation and is suitable for the maintenance treatment of adult patients with chronic obstructive pulmonary disease (COPD). The marketed formulations include inhalation preparations (single and compound), including Indacaterol Maleate inhalation powder and Indacaterol Bromide inhalation powder